Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

von Hippel-Lindau Disease 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Medullary 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Cyclophosphamide 27fludarabine phosphate 19Whole-Body Irradiation 18Peripheral Blood Stem Cell Transplantation 18Etoposide 17Rituximab 15Brentuximab Vedotin 15Mycophenolic Acid 14Tacrolimus 13Doxorubicin 12Vincristine 11Prednisone 11Methotrexate 11Busulfan 11Melphalan 9Antilymphocyte Serum 9Cyclosporine 8Filgrastim 6Carboplatin 6Sirolimus 5Radiotherapy 5Lenalidomide 5Gene Expression Profiling 5Cytarabine 5merphos 4Vorinostat 4Immunohistochemistry 4Ifosfamide 4Gemcitabine 4Flow Cytometry 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large-Cell, Anaplastic × tanespimycin × Clear all
NCT00117988 2014-05-30

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 5 charts
Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡